Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Challenges to curing primary brain tumours

The seven key challenges summarized in this Position Paper are intended to serve as foci for future research and investment in brain tumours

Research

Diffuse Intrinsic Pontine Glioma

This chapter summarizes recent advances in diffuse intrinsic pontine glioma and potential novel therapies

Research

Parental occupational exposure to low-frequency magnetic fields and risk of leukaemia in the offspring: Findings from the Childhood Leukaemia International Consortium

We did not find any associations between parental occupational extremely low-frequency magnetic fields exposure and childhood leukaemia

Research

Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma

Bevacizumab is well tolerated and appears most effective for rapid tumor control to preserve vision and improve morbidity

Research

The Australian and New Zealand Children's Haematology/Oncology Group Biobanking Network

The ANZCHOG-BN was developed to improve and streamline access to high quality pediatric and adolescent/young adult cancer biospecimens for cancer research

Research

Bilateral murine tumor models for characterizing the response to immune checkpoint blockade

This protocol describes bilateral murine tumor models that display a symmetrical yet dichotomous response to immune checkpoint blockade

Research

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy

In this review we explore the current literature about the predictive characteristics of the tumor microenvironment and discuss therapeutic approaches

Research

Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia

The aim of our study was to investigate whether CBL0137 has potential as a therapeutic and chemopotentiating compound in MLL-r leukemia

Research

Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia

Our study provides evidence that OT-82 is a promising new therapeutic strategy for a broad spectrum of high-risk pediatric acute lymphoblastic leukemia